We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
-8.48%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$1.38B
AUM Growth
+$216M
Cap. Flow
+$438M
Cap. Flow %
31.76%
Top 10 Hldgs %
59.8%
Holding
50
New
13
Increased
11
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$105M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$65M
3
AMRN
Amarin Corp
AMRN
+$61.1M
4
SWTX
SpringWorks Therapeutics
SWTX
+$49.1M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$34.7M

Top Sells

Rank Stock Value
1
MRSN
Mersana Therapeutics
MRSN
+$1.17M

Sector Composition

Rank Sector Weight
1 Healthcare 78.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONCE
1
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$160M 11.6%
1,650,000
+1,050,000
+175% +$105M
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$134M 9.69%
1,715,560
– –
ONC
3
BeOne Medicines Ltd
ONC
$32.8B
$113M 8.21%
925,000
+25,000
+3% +$3.32M
IMMU
4
DELISTED
Immunomedics Inc
IMMU
$92.2M 6.68%
6,950,000
+383,000
+6% +$5.63M
ODT
5
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$87.5M 6.35%
3,363,377
– –
ALLK
6
DELISTED
Allakos
ALLK
$53.1M 3.85%
675,000
+200,000
+42% +$13.2M
AMRN
7
Amarin Corp
AMRN
$299M
$53.1M 3.85%
+175,000
New +$61.1M
DBVT
8
DBV Technologies
DBVT
$799M
$45.6M 3.3%
530,000
– –
SWTX
9
DELISTED
SpringWorks Therapeutics
SWTX
$45M 3.26%
+2,075,905
New +$49.1M
SRPT icon
10
Sarepta Therapeutics
SRPT
$1.57B
$41.4M 3%
+550,000
New +$65M
SLDB icon
11
Solid Biosciences
SLDB
$794M
$40.3M 2.92%
259,791
+28,240
+12% +$3.2M
MDCO
12
DELISTED
Medicines Co
MDCO
$37.5M 2.72%
750,000
– –
ESPR
13
DELISTED
Esperion Therapeutics
ESPR
$35.7M 2.59%
975,000
– –
GOSS icon
14
Gossamer Bio
GOSS
$82.9M
$34.8M 2.53%
2,075,000
+200,000
+11% +$3.98M
QURE icon
15
uniQure
QURE
$3.03B
$34.1M 2.47%
865,400
+250,000
+41% +$14.4M
PTCT icon
16
PTC Therapeutics
PTCT
$5.64B
$33.8M 2.45%
1,000,000
– –
BMRN icon
17
BioMarin Pharmaceuticals
BMRN
$11.6B
$30.3M 2.2%
+450,000
New +$34.7M
ARGX icon
18
argenx
ARGX
$53.4B
$22.8M 1.65%
200,000
– –
BCEL
19
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$21.2M 1.54%
1,733,583
– –
MIST icon
20
Milestone Pharmaceuticals
MIST
$138M
$20.6M 1.49%
1,102,194
– –
WVE icon
21
Wave Life Sciences
WVE
$1.09B
$20.5M 1.49%
1,000,000
– –
FOLD
22
DELISTED
Amicus Therapeutics
FOLD
$18.6M 1.35%
2,325,000
– –
RCKT icon
23
Rocket Pharmaceuticals
RCKT
$340M
$17.1M 1.24%
1,466,051
– –
APLS
24
DELISTED
Apellis Pharmaceuticals
APLS
$16.9M 1.22%
+700,000
New +$19.3M
PRVL
25
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$13.8M 1%
1,123,105
– –
1
2

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q3 2019 Portfolio in Review

As of Q3 2019, Boxer Capital held 50 positions worth $1.38B, up 19% from $1.16B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Boxer Capital deployed $438M of net new capital in Q3 2019, opening 13 new positions and adding to 11 existing holdings. Its largest new stake was Sarepta Therapeutics: 550,000 shares worth $41.4M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 83% a quarter earlier.

On the sell side, the largest reduction was Mersana Therapeutics, an estimated $1.17M trimmed.

  • Boxer Capital's largest Q3 2019 buy was Sarepta Therapeutics: 550,000 shares worth $41.4M.
  • Boxer Capital added most to Spark Therapeutics, Inc. Common Stock in Q3 2019, an estimated $105M increase.
  • Boxer Capital's biggest Q3 2019 reduction was Mersana Therapeutics, cutting an estimated $1.17M.
  • Boxer Capital's ten largest holdings make up 60% of its $1.38B portfolio in Q3 2019.
  • Boxer Capital opened 13 new positions and closed 1 in Q3 2019.
  • Boxer Capital's portfolio value rose 19% quarter-over-quarter to $1.38B.

Based on Boxer Capital's 13F filing for Q3 2019, filed 14 Nov 2019.